Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 microdose study of TTX-MC138-NODAGA-Cu64 in advanced solid tumors
NCT05908773Phase 1Completed
- Sponsor
- TransCode Therapeutics, Inc.
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Nanoparticles, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TTX-MC138-NODAGA-Cu64 in solid tumor, sponsored by TransCode Therapeutics, Inc. Primary endpoints: Injected Dose, Biodistribution of TTX-MC138-NODAGA-Cu64 and 1 more. Started Apr 2023; status: completed.
02
Drugs
TTX-MC138-NODAGA-Cu64
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05908773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908773.